Oncobiologics Receives Positive Nasdaq Listing Determination

Pharmaceutical Investing

Oncobiologics (NASDAQ:ONS) announced that on February 13, 2018, the Company received formal notice that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for the transfer of its listing from The Nasdaq Global Market to The Nasdaq Capital Market, pursuant to an extension through May 15, 2018 to evidence compliance with all applicable requirements …

Oncobiologics (NASDAQ:ONS) announced that on February 13, 2018, the Company received formal notice that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for the transfer of its listing from The Nasdaq Global Market to The Nasdaq Capital Market, pursuant to an extension through May 15, 2018 to evidence compliance with all applicable requirements for continued listing on Nasdaq, including the applicable $35 million market capitalization requirement.

As quoted in the press release:

The Company’s current market capitalization is approximately $30 million. The Company’s common stock and Series A and Series B warrants will begin trading on The Nasdaq Capital Market tier under their respective current trading symbols, ONS, ONSIW and ONSIZ, effective with the open of business on Thursday, February 15, 2018.

Click here to read the full press release.

The Conversation (0)
×